Adductor canal block and local infiltration analgesia combined with iPACK for postoperative pain, knee function, and muscle strength after anterior cruciate ligament reconstruction: a randomized controlled trial.

Adductor canal block and local infiltration analgesia combined with iPACK for postoperative pain, knee function, and muscle strength after anterior cruciate ligament reconstruction

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032738

Enrollment

Unknown

Registered

2020-05-08

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ACL reconstruction

Interventions

A:Adductor canal block and local infiltration analgesia

B:Adductor canal block and local infiltration analgesia combined with iPACK

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) The patients undergoing ACL reconstruction; (2) Normal platelet and coagulation function preoperatively; (3) Normal intravenous ultrasound in the lower extremities preoperatively; (4) To be able to and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Systemic infections such as pulmonary infection or urinary tract infection are not controlled preoperatively; (2) Abnormal immune function or combined immune-related disease preoperatively; (3) Abnormal inflammatory index preoperatively (C-reactive protein > 20 mg/L); (4) Abnormal fibrinolysis index preoperatively (FDP > 5mg/L); (5) Discontinuation of oral anticoagulants or aspirin less than 1 week; (6) Allergy to tranexamic acid (TXA) or dexamethasone or have contraindications; (7) Patients at high risk of thrombosis; (8) History of deep vein thrombosis (VTE, calf muscle vein thrombosis or superficial vein thrombosis, pulmonary embolism); (9) Serious liver and kidney dysfunction.

Design outcomes

Primary

Measure	Time frame
VAS pain score;	—

Secondary

Measure	Time frame
Morphine consumption;Quadriceps muscle strength;Walking distance;Range of motion;PONV;color Doppler Ultrasonic (CDU) examination in lower extremity;IKDC;Lysholm;Satisfaction scores;Sleep quality;Time for First Analgesic Request;Opioid-Related Adverse Effects;	—

Countries

China

Contacts

Public ContactJian Li

West China Hospital, Sichuan University

18980601388@163.com+86 18980601388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026